Neos Therapeutics is an oral drug delivery company developing controlled time-release technologies. The Company develops, manufactures, and commercializes innovative extended-release products using its proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. 

Neos Therapeutics has two FDA-approved products for the treatment of ADHD and both utilize its extended-release ODT technology.

The Company's growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.

Employee Rating

2.8More
TypePublic
HQGrand Prairie, US
Founded2008
Size (employees)138 (est)+3%
Websiteneostx.com
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Neos Therapeutics

Jerry McLaughlin

Jerry McLaughlin

Chief Executive Officer and Director
Richard Eisenstadt

Richard Eisenstadt

CFO
Thomas McDonnell

Thomas McDonnell

Chief Commercial Officer
Dorothy Engelking

Dorothy Engelking

Vice President of Regulatory Affairs
Russ McMahen

Russ McMahen

Senior Vice President of Research & Development
Margaret Cabano

Margaret Cabano

Vice President of Operations
Show more

Neos Therapeutics Office Locations

Neos Therapeutics has offices in Grand Prairie and Blue Bell
Grand Prairie, US (HQ)
2940 N. Highway 360
Blue Bell, US
130 1787 Sentry Pkwy W
Show all (2)
Report incorrect company information

Neos Therapeutics Financials and Metrics

Neos Therapeutics Revenue

Neos Therapeutics's revenue was reported to be $9.15 m in FY, 2016 which is a 141.4% increase from the previous period.
USD

Net income (Q3, 2018)

(12.7m)

EBIT (Q3, 2018)

(10.5m)

Market capitalization (17-Jan-2019)

103.3m

Closing stock price (17-Jan-2019)

2.1

Cash (30-Sep-2018)

16.6m

EV

146.7m
Neos Therapeutics's current market capitalization is $103.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

3.8m9.2m

Revenue growth, %

141%

Cost of goods sold

5.5m11.4m12.4m

Gross profit

(1.8m)(2.3m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.5m221.0k

Cost of goods sold

2.3m1.7m2.3m4.6m2.6m2.4m5.2m7.0m7.0m

General and administrative expense

1.7m2.1m3.6m3.5m3.1m3.5m3.3m3.9m3.3m3.7m3.5m

R&D expense

2.1m2.7m2.3m4.3m2.9m1.7m3.7m1.8m1.7m2.4m2.0m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

90.8m24.4m32.0m

Accounts Receivable

1.2m

Inventories

2.5m5.8m13.5m

Current Assets

98.2m55.3m82.6m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(30.8m)(83.3m)(66.2m)

Inventories

2.5m(3.2m)(7.7m)

Accounts Payable

4.8m3.0m3.0m

Cash From Operating Activities

(70.6m)(53.3m)
USDY, 2018

EV/EBIT

-14 x

EV/CFO

-4.1 x

EV/FCF

-3.9 x

Debt/Assets

0.8 x
Show all financial metrics
Report incorrect company information

Neos Therapeutics News and Updates

Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation

DALLAS and FORT WORTH, Texas, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disint…

Neos Therapeutics Reports Third Quarter 2018 Financial Results

Company to host conference call today at 8:30am ET 

Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018

DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the opening of U.S. financial markets on Friday, November 9, 2018. Neos management will host a conference call …

Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting

DALLAS and FORT WORTH, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release Orally-Disintegrating Tablets, at the 65th Annual Meeting of the American Academy of Child & Ad…

Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)

Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options
Show more
Report incorrect company information

Neos Therapeutics Company Life and Culture

Report incorrect company information

Neos Therapeutics Frequently Asked Questions

  • When was Neos Therapeutics founded?

    Neos Therapeutics was founded in 2008.

  • Who are Neos Therapeutics key executives?

    Neos Therapeutics's key executives are Jerry McLaughlin, Richard Eisenstadt and Thomas McDonnell.

  • How many employees does Neos Therapeutics have?

    Neos Therapeutics has 138 employees.

  • Who are Neos Therapeutics competitors?

    Competitors of Neos Therapeutics include Proteo, Medizone International and RespireRx Pharmaceuticals.

  • Where is Neos Therapeutics headquarters?

    Neos Therapeutics headquarters is located at 2940 N. Highway 360, Grand Prairie.

  • Where are Neos Therapeutics offices?

    Neos Therapeutics has offices in Grand Prairie and Blue Bell.

  • How many offices does Neos Therapeutics have?

    Neos Therapeutics has 2 offices.